A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer
Phase 1 : To evaluate MTD(Maximal tolerated dose)and DLT(Dose limiting Toxicity) of Belotecan and Ifosfamide.

Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide.
Small Cell Lung Cancer
DRUG: Belotecan and Ifosfamide
MTD (maximal tolerated dose), one year
DLT(dose-limiting toxicity), one year
Response rate, one year|PFS(Progression-Free-Survival), one year|Overall Survival, one year|Number of participants with adverse events, one year
Phase 1 : To evaluate MTD(Maximal tolerated dose)and DLT(Dose limiting Toxicity) of Belotecan and Ifosfamide.

Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide.